檢索結果 - Geoffrey R. Oxnard

Refine Results
  1. 1
    New Targetable Oncogenes in Non–Small-Cell Lung Cancer

    New Targetable Oncogenes in Non–Small-Cell Lung Cancer 由 Geoffrey R. Oxnard, Adam F. Binder, Pasi A. Jänne

    出版 2013
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  2. 2
    Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer

    Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer 由 Geoffrey R. Oxnard, Cloud P. Paweletz, Lynette M. Sholl

    出版 2016
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  3. 3
    Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review

    Application of Plasma Genotyping Technologies in Non–Small Cell Lung Cancer: A Practical Review 由 Adrian G. Sacher, Kimberly M. Komatsubara, Geoffrey R. Oxnard

    出版 2017
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  4. 4
    Circulating tumor DNA analysis in the era of precision oncology

    Circulating tumor DNA analysis in the era of precision oncology 由 Rabih Said, Nicolas Guibert, Geoffrey R. Oxnard, Apostolia M. Tsimberidou

    出版 2020
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer 由 Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William Pao

    出版 2011
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  6. 6
    Clinical Implications of Variant ALK FISH Rearrangement Patterns

    Clinical Implications of Variant ALK FISH Rearrangement Patterns 由 Xin Gao, Lynette M. Sholl, Mizuki Nishino, Jennifer Heng, Pasi A. Jänne, Geoffrey R. Oxnard

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation

    Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation 由 Russell W. Jenkins, Geoffrey R. Oxnard, Sheryl K. Elkin, Elroy Sullivan, Jennifer Carter, David A. Barbie

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib

    Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib 由 Julia Rotow, Jessica Lee, Russell W. Madison, Geoffrey R. Oxnard, Pasi A. Jänne, Alexa B. Schrock

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Cl... 由 Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, Gregory J. Riely

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

    Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer 由 Adrian G. Sacher, Suzanne E. Dahlberg, Jennifer Heng, Stacy L. Mach, Pasi A. Jänne, Geoffrey R. Oxnard

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions

    Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions 由 Michael L. Cheng, Eirini Pectasides, Glenn J. Hanna, Heather A. Parsons, Atish D. Choudhury, Geoffrey R. Oxnard

    出版 2020
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  12. 12
    Unsuspected pulmonary embolism in lung cancer patients: Comparison of clinical characteristics and outcome with suspected pulmonary embolism

    Unsuspected pulmonary embolism in lung cancer patients: Comparison of clinical characteristics and outcome with suspected pulmonary embolism 由 Atul B. Shinagare, Yuka Okajima, Geoffrey R. Oxnard, Pamela J. DiPiro, Bruce E. Johnson, Hiroto Hatabu, Mizuki Nishino

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping 由 Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

    出版 2012
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

    Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors 由 Sarah B. Goldberg, Geoffrey R. Oxnard, Subba R. Digumarthy, Alona Muzikansky, David M. Jackman, Inga T. Lennes, Lecia V. Sequist

    出版 2013
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC

    Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC 由 Hugo J.W.L. Aerts, Patrick Großmann, Yongqiang Tan, Geoffrey R. Oxnard, Naiyer A. Rizvi, Lawrence H. Schwartz, Binsheng Zhao

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA

    Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA 由 Julianna Supplee, Marina S.D. Milan, Lee P. Lim, Kristy Potts, Lynette M. Sholl, Geoffrey R. Oxnard, Cloud P. Paweletz

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types

    Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types 由 Jake G Maule, Lani K Clinton, Ryon P. Graf, Jinpeng Xiao, Geoffrey R. Oxnard, Jeffrey S. Ross, Richard S.P. Huang

    出版 2022
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression

    When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression 由 Geoffrey R. Oxnard, Michael J. Morris, F. Stephen Hodi, Laurence H. Baker, Mark G. Kris, Alan P. Venook, Lawrence H. Schwartz

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

    "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer 由 Christian Grommes, Geoffrey R. Oxnard, Mark G. Kris, V.A. Miller, William Pao, Andrei I. Holodny, Jennifer Clarke, Andrew B. Lassman

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies

    Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies 由 Jason J. Luke, Geoffrey R. Oxnard, Cloud P. Paweletz, D. Ross Camidge, John V. Heymach, David B. Solit, Bruce E. Johnson

    出版 2014
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: